Alphatec Spine Announces Conference Call and Business Update in Advance of Attendance at the 27th Annual North American Spine S
22 Octobre 2012 - 10:05PM
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., announced today a conference call and live
webcast, scheduled for today at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time, to provide a business update in advance of the
Company's attendance at the upcoming NASS meeting to be held on
October 24th – 26th, 2012 in Dallas, Texas.
Conference call and webcast details for today are as
follows:
Conference call: (ID# 48352833) - (877) 556-5251 for domestic
callers and (720) 545-0036 for international callers.
Live webcast: Alphatec Spine website at www.AlphatecSpine.com,
Investor Relations section. The webcast will be recorded and will
remain available on Alphatec Spine's website for at least 30
days.
On today's conference call, the Company will provide an update
on the following business topics:
- Third quarter 2012 revenue is approximately $46.8 million, or
$47.8 million on a constant currency basis, compared to $47.6
million reported in the third quarter of 2011. Total U.S. revenue
is $31.0 million, driven by continued strong contributions from the
Company's Biologics business. International revenue is
approximately $15.9 million, or $16.8 million on a constant
currency basis, compared to $14.9 million reported in the third
quarter of 2011, reflecting continued strong growth in Japan.
- The acquisition of certain assets of Phygen, LLC is nearing
completion. The required number of Phygen's members have voted in
favor of the transaction and both Phygen and Alphatec Spine have
signed the Asset Purchase Agreement. Alphatec Spine anticipates
closing the acquisition in the next few weeks.
Alphatec Spine will release its full third quarter results on
November 1, 2012 at 1:05 p.m. Pacific Time / 4:05 p.m. Eastern
Time. A conference call (ID# 46731968) and live webcast have been
scheduled to discuss those results and is scheduled for 2:00 p.m.
Pacific Time / 5:00 p.m. Eastern Time. Individuals interested in
listening to the conference call may do so by dialing (877)
556-5251 for domestic callers and (720) 545-0036 for international
callers. The live webcast will be available online from the
investor relations section of the Alphatec Spine website at
www.AlphatecSpine.com. The webcast will be recorded and will remain
available on the investor relations section of Alphatec Spine's
website for at least 30 days.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device
company that designs, develops, manufactures and markets products
for the surgical treatment of spine disorders, primarily focused on
the aging spine. The Company's mission is to combine
world-class customer service with innovative, surgeon-driven
products that will help improve the aging patient's quality of
life. The Company is poised to achieve its goal through new
solutions for patients with osteoporosis, stenosis and other aging
spine deformities, improved minimally invasive products and
techniques and integrated biologics solutions. In addition to
its U.S. operations, the Company also markets its products in over
50 international markets through its affiliate, Scient'x S.A.S.,
via a direct sales force in France, Italy and the United Kingdom
and via independent distributors in the rest of Europe, the Middle
East and Africa. In Latin America, the Company conducts its
business through its subsidiary, Cibramed Produtos Medicos. In
Japan, the Company markets its products through its subsidiary,
Alphatec Pacific, Inc. In the rest of Asia and Australia, the
Company sells its and Scient'x's products through its and
Scient'x's distributors.
The Alphatec Holdings, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3520
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no
assurance that actual results or business conditions will not
differ materially from those projected or suggested in such
forward-looking statements as a result of various factors. Forward
looking statements include references to Alphatec Spine's third
quarter 2012 revenue; and the closing of the Phygen, LLC
acquisition. The words "believe," "will," "should," "expect,"
"intend," "estimate" and "anticipate," variations of such words and
similar expressions identify forward-looking statements, but their
absence does not mean that a statement is not a forward-looking
statement. The important factors that could cause actual
operating results to differ significantly from those expressed or
implied by such forward-looking statements include, but are not
limited to; the uncertainty of success in licensing or developing
and commercializing new products or products currently in Alphatec
Spine's pipeline; failure to achieve acceptance of Alphatec Spine's
products by the surgeon community including Alphatec's Biologics
products; failure to successfully implement streamlining activities
to create anticipated operational savings; failure to successfully
begin in-house manufacturing of certain products; failure to obtain
FDA clearance or approval for new products, or unexpected or
prolonged delays in the process; Alphatec Spine's ability to
develop and expand its U.S. and/or global revenues, including
international revenues, particularly in Japan; continuation of
favorable third party payor reimbursement for procedures performed
using Alphatec Spine's products; unanticipated expenses or
liabilities or other adverse events affecting cash flow or Alphatec
Spine's ability to successfully control its costs or achieve
profitability; uncertainty of additional funding; Alphatec Spine's
ability to compete with other competing products and with emerging
new technologies; product liability exposure; failure to meet all
financial obligations in the Cross Medical Settlement or its credit
agreement; patent infringement claims and claims related to
Alphatec Spine's intellectual property or products sold by Alphatec
Spine. Please refer to the risks detailed from time to time in
Alphatec Spine's SEC reports, including its Annual Report Form 10-K
for the year ended December 31, 2011, filed on March 5, 2012 with
the Securities and Exchange Commission, as well as other filings on
Form 10-Q and periodic filings on Form 8-K. Alphatec Spine
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
CONTACT: Investor/Media Contact:
Mark Francois
Senior Director, Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
mfrancois@AlphatecSpine.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024